Paul Monk

1.3k total citations
50 papers, 390 citations indexed

About

Paul Monk is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Paul Monk has authored 50 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 12 papers in Surgery. Recurrent topics in Paul Monk's work include Cancer Immunotherapy and Biomarkers (17 papers), Prostate Cancer Treatment and Research (17 papers) and Bladder and Urothelial Cancer Treatments (11 papers). Paul Monk is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Prostate Cancer Treatment and Research (17 papers) and Bladder and Urothelial Cancer Treatments (11 papers). Paul Monk collaborates with scholars based in United States, United Kingdom and India. Paul Monk's co-authors include Amir Mortazavi, Steven K. Clinton, Charles L. Shapiro, Eric H. Kraut, Miguel A. Villalona‐Calero, Gregory A. Otterson, Manisha H. Shah, P. Nadella, Katharine A. Collier and Yuanquan Yang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Paul Monk

47 papers receiving 389 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Monk United States	11	228	167	104	82	59	50	390
Wenxiao Jia China	10	219 1.0×	157 0.9×	95 0.9×	42 0.5×	88 1.5×	25	374
Prasanth Reddy United States	8	205 0.9×	158 0.9×	101 1.0×	88 1.1×	117 2.0×	28	386
Robert Alter United States	10	264 1.2×	206 1.2×	132 1.3×	60 0.7×	88 1.5×	29	466
Brenda Dickow United States	11	215 0.9×	280 1.7×	162 1.6×	57 0.7×	94 1.6×	20	449
Brigida Anna Maiorano Italy	15	343 1.5×	125 0.7×	125 1.2×	88 1.1×	67 1.1×	58	531
Nergiz Dağoğlu Türkiye	11	244 1.1×	183 1.1×	67 0.6×	170 2.1×	38 0.6×	35	440
Audrey Simonaggio France	10	445 2.0×	278 1.7×	104 1.0×	48 0.6×	51 0.9×	23	567
Smitha Menon United States	11	300 1.3×	128 0.8×	134 1.3×	29 0.4×	73 1.2×	18	474
Yasmine Baca United States	10	174 0.8×	83 0.5×	94 0.9×	51 0.6×	75 1.3×	56	292
Mengdie Yuan United States	5	308 1.4×	146 0.9×	76 0.7×	67 0.8×	131 2.2×	10	455

Countries citing papers authored by Paul Monk

Since Specialization

Citations

This map shows the geographic impact of Paul Monk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Monk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Monk more than expected).

Fields of papers citing papers by Paul Monk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Monk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Monk. The network helps show where Paul Monk may publish in the future.

Co-authorship network of co-authors of Paul Monk

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Monk. A scholar is included among the top collaborators of Paul Monk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Monk. Paul Monk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kelly, William Kevin, Sandy Srinivas, Joseph Maly, et al.. (2025). Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 43(5_suppl). 1 indexed citations

Hong, Feng, Yuanquan Yang, Eric A. Singer, et al.. (2025). Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches. Cancer Drug Resistance. 8. 9–9. 5 indexed citations

Xu, Menglin, Elshad Hasanov, Katharine A. Collier, et al.. (2024). Association of genomic alterations with clinical outcomes following lutetium-177-PSMA vipivotide tetraxetan in men with metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology. 42(16_suppl). 5057–5057. 1 indexed citations

Collier, Katharine A., Peng Wang, Zihai Li, et al.. (2023). Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells. 13(1). 34–34. 25 indexed citations

Aggarwal, Rahul, Jingsong Zhang, Paul Monk, et al.. (2023). First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.. Journal of Clinical Oncology. 41(16_suppl). TPS5109–TPS5109. 1 indexed citations

Collier, Katharine A., Herbert B. Newton, Erinn M. Hade, et al.. (2021). A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 87(5). 599–611. 20 indexed citations

Monk, Paul, et al.. (2021). Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report. BMC Urology. 21(1). 51–51. 7 indexed citations

Kaliński, Paweł, Claire F. Verschraegen, Steven K. Clinton, et al.. (2020). 156P High TLR3 expression predicts improved survival in patients with clear cell renal cell carcinoma. Annals of Oncology. 31. S301–S301.

Yin, Ming, Petros Grivas, Qi-En Wang, et al.. (2020). Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer. The Oncologist. 25(8). 680–688. 12 indexed citations

10.

Zhang, Jingsong, David D. Chism, Scott T. Tagawa, et al.. (2019). Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(7_suppl). 197–197. 1 indexed citations

11.

Monk, Paul, Glenn Liu, Walter M. Stadler, et al.. (2018). Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Investigational New Drugs. 36(5). 919–926. 9 indexed citations

12.

Unger, Joseph M., Katherine Griffin, Gary Donaldson, et al.. (2018). Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). Journal of Patient-Reported Outcomes. 2(1). 27–27. 7 indexed citations

13.

Appleman, Leonard J., Theodore F. Logan, Daniel P. Normolle, et al.. (2018). Targeting autophagy and immunotherapy with hydroxychloroquine and interleukin 2 in patients with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group study.. Journal of Clinical Oncology. 36(5_suppl). 106–106. 3 indexed citations

14.

Apolo, Andrea B., Amir Mortazavi, Mark N. Stein, et al.. (2017). A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.. Journal of Clinical Oncology. 35(6_suppl). 293–293. 36 indexed citations

15.

Apolo, Andrea B., Amir Mortazavi, Mark N. Stein, et al.. (2016). A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. Annals of Oncology. 27. vi266–vi266. 12 indexed citations

16.

Mikhail, Sameh, Maryam B. Lustberg, Amy S. Ruppert, et al.. (2015). Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemotherapy and Pharmacology. 76(5). 1005–1012. 2 indexed citations

17.

Lam, Elaine T., Michael K. Wong, Neeraj Agarwal, et al.. (2014). Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Immunotherapy. 37(7). 360–365. 9 indexed citations

18.

Monk, Paul, Elaine T. Lam, Amir Mortazavi, et al.. (2014). A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma. Journal of Immunotherapy. 37(3). 180–186. 11 indexed citations

19.

Martin, Ludmila Katherine, Tanios Bekaii‐Saab, Paul Monk, et al.. (2013). A Phase I Dose Escalation and Pharmacodynamic Study of SU5416 (Semaxanib) Combined with Weekly Cisplatin and Irinotecan in Patients with Advanced Solid Tumors. Oncology Research and Treatment. 36(11). 657–660. 5 indexed citations

20.

Dangle, Pankaj, et al.. (2008). Low grade papillary transitional cell carcinoma pelvic recurrence masquerading as high grade invasive carcinoma, ten years after radical cystectomy. World Journal of Surgical Oncology. 6(1). 103–103. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact